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Abstract
Objectives: The aim of this study was to present a rare neoplasm, Primary myoepithelial carcinoma arising from
the palate, and to review its diagnostic criteria, pathologic and clinical characteristics, treatment options and
prognosis.
Clinical Presentation and Intervention: Myoepitheliomas are tumors arising from myoepithelial cells mainly or
exclusively. Myoepitheliomas mostly occur in salivary glands, as well as in breast, skin, and lung. Case of
myoepitheliomas in palate has rarely been reported. Myoepithelial carcinoma is malignant counterpart of
myoepitheliomas. Adenomyoepithelioma is also a different disease from myoepitheliaomas.
Immunohistochemically, tumor cells of myoepithelial carcinoma express not only epithelial markers such as
cytokeratin, epithelial membrane antigen (EMA), but also markers of smooth muscle origin such as calponin. The
immunohistochemical criteria of myoepithelial differentiation are double positive for both cytokeratins and one or
more myoepithelial immunomarkers (i.e., S-100 protein, calponin, p63, GFAP, maspin, and actins). Myoepithelial
carcinomas of salivary and breast demonstrate copy number gains and gene deletion. The overall prognosis of
myoepithelial carcinoma is poor. There is rarely recurrence or metastasis in benign myoepithelial tumors. Complete
excision with tumor-free margin is always the preferred treatment, while local radiation therapy and chemotherapy
are suggestive treatment options. Here, a rare case of myoepithelial carcinoma arising from the palate has been
described and discussed for the treatment and outcome. Pathological and clinical characters of myoepitheliomas
are also compared and discussed.
Conclusion: The case report serves to increase awareness and improve the index of diagnosis and treatment of
myoepitheliomas.
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1. Background
Myoepitheliomas are tumors arising from myoepithelial
cells lacking ductal differentiation which exhibit both
epithelial and smooth muscle cell characteristics. Benign
myoepithelial tumors were seen mostly in extremities
and head-neck region, while malignant counterparts
mostly occur in the salivary gland, parotid, ans breast
tissues.
Histopathology and immunohistochemistry play criti-
cal roles in diagnosis of myoepithelial carcinoma due
to its differentiation limited to myoepithelium fre-
quently. Myoepithelioma shows solid, reticular and
trabecular arrangement histopathologically and is com-
posed of round/epithelioid or spindle cells, frequently
infiltrated by clear or plasmacytoid cells. Immunohisto-
chemistry shows general positive for both epithelial
and myogenic markers in myoepithelial carcinoma
cells.
The most common arising sites of myoepithelial carci-
noma lie in the parotid gland [1], as well as the naso-
pharynx, paranasal sinus and nasal cavity of head-neck
region [2,3]. Myoepithelial carcinoma rarely occurs in
the palate so the description is not adequate. Here we
report a rare case of myoepithelial carcinoma arising
from palate and describe its surgical and radiotherapy
management and prognosis. Features of myoepithelio-
mas are also discussed through review the previous
literature.
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2.1 clinical reviews
The patient was a 75-year-old male, and there were
unremarkable medical records for him and his family
members. One year ago an unconscious eminentia was
found in his right palate. There was no pain, discomfort
or difficulties in eating or swallowing. The eminentia
grew gradually and at last turned to a hard, ill-defined,
oval mass with the diameter of 2.2 cm in the right
palate, showing a blue black fleck on its surface mem-
brane. There was no ulceration or mucosal erosion on
the mass which demonstrated immovable and tender-
ness. Neither history of known malignant diseases, nor
neoplasms by full-body imaging was found in this
patient.
2.2 Pathological and immunohistochemical findings
Histological examinations were performed after surgery
to confirm the diagnosis. The tumor showed a 22.52 ×
25 mm, lobulated neoplasm with an off-white coarser
surface gross appearance. Colors from red to gray were
seen in a vertical section of the tumor. Through ultra-
structural examination, the tumor cells showed macro-
nuclei, multiple nuclei, increased mitosis, high density
nuclear chromatin, and the tumor cell nuclei were circu-
lar with abundant euchromatin and a conspicuous
nucleolus. Cubic cells (Figure 1a) and local cystic degen-
eration and hemorrhage were observed in the tumor,
and were arranged in film (Figure 1b) and deeply
stained in nucleus. The size of the nucleus varied from
cell to cell. Some tumor cells showed translucent cyto-
plasm and tubular structure (Figure 1c). Cells showed
oval and different sizes (Figure 1d) and were ill-defined
(Figure 1e). Mitotic figure and delicate chromatin was
found in nucleus (Figure 1f). Vacuolated cytoplasm and
translucent cytoplasm were observed.
Immunohistochemical staining showed the tumor was
strongly positive for Cytokeratin, S-100, and Calponin,
and was negative for epithelial membrane antigen
(EMA), glial fibrillary acidic protein (GFAP), human
melanoma black45 (HMB45), desmin, and microglobulin
(Figure 2). Calponin and S-100 were highly expressed in
the cytoplasm of myoepithelial cells, while Cytokeratin
was expressed in the nucleus (in Figure 2a, b, c); Cyto-
keratin is expressed in both gland duct epithelial cells
and myoepithelial cells. In our case, cytokeratin is posi-
tively stained in nucleus of myoepithelial cells (Figure
2c) which is consistent with the major diagnostic criteria
of myoepithelial carcinoma.
2.3 The treatment and prognosis
Surgery is always the first choice of treatment for
myoepithelial carcinoma, including extended tumor
resection in the right palate and tumor exploratory in
the maxillofacial/deep neck. Biomembrane was
implanted and mass with incomplete capsule and
intact bones were found. The whole layers of mucous
membrane were incised at 1 cm away from the tumor
Figure 1 HE staining. (b): 10 ×; (C), (d): 20 ×; (e),(f): 40 ×.
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excised along the bone surface. After the surgery, both
light microscope evaluation (routine HE staining) and
immunohistochemical analysis using specific antibodies
were carried out to confirm the pathological diagnosis
of myoepithelial carcinoma. Focal external beam radia-
tion-therapy was subsequently performed on the
patient in the target regions of the tumor bed and
regional lymph drainage area. The total tissue dose
was 50Gy/25f (Figure 3), including the first target
region (shown by black line in Figure 3) of 36Gy/18f
and the second target region (the cervical spinal cord
was sheltered, shown by red line in Figure 3) of 14Gy/
7f, followed by 4 cycles of chemotherapy with Camp-
tothecin. There was no evidence of local recurrence or
distant metastasis in a period of 2-year follow-up.
3. Discussion
3.1 General concept of Myoepitheliomas
Myoepitheliomas are tumors arising from myoepithelial
cells predominantly or exclusively. Myoepithelial cells
are normally located between the epithelial cells and the
basal lamina of acini and ducts of salivary glands, breast,
and sweat glands of the skin. Thus the tumors mostly
occur in the salivary glands, as well as in the breast,
skin, and lung.
Figure 2 Immunohistochemical staining, Brown particle was regarded as positive staining signal. (a), Immunostaining of Calponin (200
×), Calponin antibody was from Zhong Shan and was 1:100 diluted; (b), Immunostaining of S-100 (200 ×), S-100 antibody was from Zhong Shan
and was 1:80 diluted; (c), Immunostaining of cytokeratin (200 ×), CK antibody was from MaiXin and was 1:60 diluted; (d), Immunostaining of
desmin (200 ×), desmin antibody was from Zhong Shan and was 1:80 diluted; (e), Immunostaining of EMA (200 ×), EMA antibody was from
Zhong Shan and was 1:80 diluted; (f), Immunostaining of GFAP (200 ×), GFAP antibody was from MaiXin and was 1:80 diluted; (g),
Immunostaining of human melanoma black45(HMB45) (200 ×), HMB45 antibody was from MaiXin and was 1:80 diluted; (h), Immunostaining of
Ki-67 (200 ×), Ki-67 antibody was from Zhong Shan and was 1:80 diluted; (i), Immunostaining of microglobulin (200 ×), microglobulin antibody
was from Zhong Shan and was 1:80 diluted.
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malignant mixed tumor, however, exclusive myoepithelial
differentiation makes it a distinctly separated tumor in
pathology [4]. According to the WHO classification,
myoepithelial carcinoma is referred to those lesions
‘’composed almost exclusively of tumor cells with myoe-
pithelial differentiation’’. Therefore, a tumor containing
frequent true luminal differentiation should be excluded
from the category of purely myoepithelial carcinoma’’ [5].
Myoepitheliaomas and their malignant counterpart,
myoepithelial carcinoma are distinct concepts from ade-
nomyoepitheliomas [6]. Malignant adeno-myoepithe-
lioma, adeno-myoepithelioma (combination of adenoma
and myoepithelioma), epithelialmyoepithelial adenoma,
and epithelial-myoepithelial carcinoma are the terms
having exactly the same meaning [7]. However, when
the myoepithelial cells were the major component of
breast adenomyoepithelioma, it is usually called myoe-
pithelial carcinoma.
There are no definite histological criteria for discrimi-
nating The benign and malignant myoepitheliomas can
not be discriminated histologically. Indications of malig-
nancy are based on features such as nuclear atypia, high
mitotic rate and infiltrative growth into adjacent tissues.
Currently, benign and malignant myoepitheliomas are
differentiated by mitotic count, presence of invasive
growth, cellular polymorphism, tumour necrosis, or
their combination.
Compared with myoepitheliaomas, myoepithelial carci-
noma shows aggressiveness and recurrence even after
adequate therapy, and is disproportionately common in
pediatric age group and has an aggressive clinical course
[8]. Clinical presentation of myoepithelial carcinoma
depends on its location. The growth pattern of myoe-
pithelial carcinoma is generally multinodular, which
comprise solid and sheet-like growths of tumor cells,
with myxoid or collagenous/hyaline background
frequently.
3.1.1 Differences between Myoepitheliomas and
Adenomyoepithelioma
Adenomyoepithelioma is characterized by simultaneous
proliferation of epithelial and myoepithelial elements.
According to the pathologists, other diagnostic terms
with the same meaning have been used for adenomyoe-
pithelioma of different organs, including adeno-myoe-
pithelioma, malignant adeno-myoepithelioma,
epithelialmyoepithelial adenoma, and epithelial-myoe-
pithelial carcinoma [7]. But adenomyoepitheliomas are
different concept from myoepitheliaomas and their
malignant counterpart, myoepithelial carcinoma. Immu-
nohistochemistry staining of adenomyoepithelioma
demonstrates high expression of myoepithelial compo-
nent such as S100 protein, Calponin, smooth muscle
actin or/and GFAP, and negative expression of epithelial
markers. The epithelial component usually reacts with
cytokeratins and EMA, but is non-reactive with S100
and smooth muscle actin.
3.1.2 Differences between Myoepitheliomas and
Pleomorphic adenoma
As the most common minor salivary gland tumor
(accounting for 40% of cases), pleomorphic adenoma
shows epithelial/ductal cells in its tissues. These cells
are small and cuboidal arranged in flat sheets or trabe-
culae that can undergo squamous, oncocytic, or sebac-
eous metaplasia. Myoepithelial cells are usually also
present and can be spindled, or plasmacytoid and are
found in clusters, singly, or within the chondromyxoid
matrix. The presence of chondromyxoid matrix material
is the most specific feature for making the correct diag-
nosis. There is abundant epithelial or myoepithelial cells
with minimal stroma in cells of pleomorphic adenomas.
The pleomorphic adenoma often show 8q12 and 12q13-
q15 alterations cytogenetically, The relative lack of ducts
and chondromyxoid stroma makes pleomorphic ade-
noma distinguished from myoepithelioma, which is
composed almost exclusively of myoepithelial cells.
3.2 Histological features of Myoepitheliomas
In four major histological subtypes of myoepithelioma
(epithelioid, spindle cell, plasmacytoid, and clear cell),
the histological and ultrastructural features are well
established, howwver, the cytologic criteria are obscure
[9].
Myoepithelial cells are characterized by filaments on
the basal site and pinocytotic vesicles at the ultrastruc-
tural level. Histologically, myoepithelial cells have varied
cell morphology, including spindle cell, epithelioid,
Figure 3 The target region of radiotherapy included the tumor
bed and regional lymph drainage area.
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These four cell types were suggested to represent differ-
ent stages in myoepithelial cell differentiation [11].
Histologically, most myoepitheliomas tumors are com-
posed of cordal or nested plamacytoid, spindled cells or
clear cells with various reticular architectures, and a
myxoid, hyalinised or collagenous stroma. Some of these
tumors show predominantly constant proliferation of
spindled or plasmacytoid cells [12].
On the contrary, myoepithelial carcinoma is histologi-
cally characterized by a multilobulated architecture
without duct formation and myoepithelial differentia-
tion. Morphologically, the tumor cells are often spindle
shaped, stellate, epithelioid, plasmacytoid (hyaline), and
occasionally vacuolated with a signet-ring-like appear-
ance. Solid sheet-like formations and trabecular or reti-
cular patterns may form by tumor cells [13].
In the myoepithelial carcinoma of salivary gland, a
m a l i g n a n tc r i t e r i ap r o p o s e db yS a v e r ai n c l u d et h ep r e -
sence of seven or more mitoses per high-power field,
tumor necrosis, and tumor infiltration of adjacent tis-
sues, which was most predictive of malignant behavior
[1].
3.3 Immunohistochemically features of Myoepitheliomas
Immunohistochemical analysis shows high expression of
epithelial markers such as cytokeratin, epithelial mem-
brane antigen (EMA), S-100 protein, and markers of
smooth muscle origin such as smooth muscle actin and
calponin on the tumor cells of myoepitheliomas. Cur-
rent immunohistochemical criteria for the confirmation
of myoepithelial differentiation are double positivity for
both cytokeratins (pan CK or preferentially basal type
C K )a n do n eo rm o r em y o e p i t helial immunomarkers (i.
e., S-100, calponin, p63, GFAP, maspin, and actins)
[14-17].
The myoepithelial origin of myoepitheliomas was con-
firmed by simultaneous positive for actin, cytokeratin
including CK-14 and Calponin along with S-100 in most
reports. Moreover, EMA, glial fibrillary acidic protein
and a variety of myogenic markers are also expressed in
myoepitheliomas. However, it must be noted that these
markers are not always positively expressed in the
tumor cells and that negative staining does not necessa-
rily exclude myoepithelial differentiation.
Immunohistochemical findings in our study are con-
sistent with those of previous reports. In our cases,
tumors immunoreactive for both cytokeratins and myoe-
pithelial markers (S-100 and Calponin) confirmed the
diagnosis of myoepithelial carcinoma and excluded the
diagnosis of epithelial-myoepithelial carcinoma.
Some other kinds of tumors can also be excluded by
Immunohistochemical findings. Histologically, spindle-
like myoepithelial cellcarcinomas make close differential
diagnoses with malignant melanoma (primary or meta-
static). Both tumors is positive for S-100 protein, but
melanoma usually does not stain positively for keratin,
HMB-45 or myogenic markers. Epitheloid sarcoma
usually stain positive only for EMA and keratins and
negative for all other markers of myoepithelial differen-
tiation, therefore, it can also be excluded [12]. Several
other tumors can also be discriminated by immunohis-
tochemistry features Foe instance, acinic cell carcinoma
show positive to PASD; High-grade mucoepidermoid
carcinoma show positive to mucicarmine, CEA, and
muscle markers; Clear-cell oncocytoma of the salivary
gland show positive to PTAH and mES mitochondrial
antigen; Clear-cell sarcoma of soft tissue in the head
and neck region show positive to melanoma-associated
antigens, and show negative to CK; Metastatic clear-cell
renal cell carcinoma show negative to intracytoplasmic
lipids, S100 protein, and muscle markers [18].
3.4 Some genetic changes in myoepithelial carcinomas
3.4.1 Genomic alterations in myoepithelial carcinomas
In general, myoepithelial carcinomas displayed slightly
more chromosomal events than benign myoepithelioma.
There are rarely genomic alterations in myoepithelial
carcinomas especially in salivary and breast tissue.
However, Hedy reported that there are differential
genomic alterations between myoepithelial carcinomas
and benign myoepitheliomas of salivary gland. The most
frequent gains of chromosomes in the benign tumors
were at 22q11.1-q13.33 (40%) and 11q23.3 (38%). The
recurrent gains of large genomic regions distinguish
myoepithelial carcinomas from their benign counter-
parts. Chromosome copy number changes such as gains
of whole chromosomes (chr. 8 in 27% and chr. 19 in
50%) or chromosome arms (20q in 32% and 22q in
50%) were frequently observed [19].
Laser capture microdissection and comparative geno-
mic hybridization were performed by Jones to report
genetic alterations in breast myoepithelial carcinomas
[20]. The loss at 16q (3/10 cases), 17p (3/10), and 11q
(2/10) were common alterations. The average chromo-
somal changes number of myoepithelial carcinoma of
the breast (2.1, range 0-4) was lower that in unselected
ductal carcinomas (8.6, range 3.6-13.8).
Magrini reported the cytogenetic features in the pri-
mary and metastatic myoepithelial carcinomas of sali-
vary gland and showed a composite karyotype in the
primary tumour: 45~46, XY, +3[cp3]/44~45, XY, -17
[cp4]/46, XY [5]. The tumor cells from metastatic
lymph-node was near-triploid and showed a complex
karyotype [21].
3.4.2 Changes of tumor suppressor gene
Both benign and malignant myoepithelial tumours of
the salivary glands show deregulated expression in
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tumour cells showed a higher expression of p16INK4a
pathway members (p16INK4a, E2F1 and cyclin D1)
compared with normal salivary gland. Furthermore,
malignant tumours expressed p53 and EZH2 at a higher
level. Recurrent tumors displayed more p53 positive
tumour cells than primary tumors. The clear cell type of
benign tumours had the highest proliferation fraction,
and the plasmacytoid cell type showed a higher percen-
tage of EZH2 positive cells. This indicates additional
inactivation of p53 is needed in neoplastic transforma-
tion and aggressive tumour growth of myoepithelial
carcinomas.
3.5 Treatment and Prognosis
Complete excision is the preferred treatment method for
myoepithelioma [1]. For myoepithelial carcinoma, com-
plete excision with tumor-free margin remains the first
choice of treatment, in spite of the possibilities of local
recurrence and distant metastasis. Local radiation ther-
apy and chemotherapy are also needed for myoepithelial
carcinoma.
Recurrence is rare for benign myoepithelial tumors,
while the overall prognosis of myoepithelial carcinoma
is poor. Several studies reported aggressive clinical beha-
viors for myoepithelial carcinoma, and the average meta-
static rate was 47% and the mortality rate was 29% after
a mean of 32 months.. Recurrence and metastasis are
m o r ec o m m o ni nc h i l d r e nt h a ni na d u l te v e nw i t ha
negative excision margin [8]. Therefore, Yu suggested
myoepithelial carcinomas of the salivary gland should be
classified as high-grade malignancies [23].
In conclusion, we reported a very rare case of myoe-
pithelial carcinoma from palate. We offer a diagnostic
reference for classifying myoepithelial carcinoma based
on the pathological characteristics. This report also pro-
vides the summary of the previous literature about
myoepitheliomas and myoepithelial carcinoma. The con-
cept, histological feature, immunohistochemistry feature,
genetic changes, treatment options and prognosis of
myoepithelial carcinoma are further discussed.
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